Is Iress Limiteds Strong FY25 Result Driving a 12.56% Share Price Surge?
Source: Kapitales Research
Highlights
• Iress Limited (ASX: IRE) shares surged nearly 12.56% at the time of writing, trading at AU$7.620 after gaining AU$0.850.
• FY25 headline UPAT rose 16.6% to AU$73.9 million, with Underlying EPS up 16.4% to 39.6 cents per share.
• Continuing Business revenue increased 6.5% to AU$504.3 million, while Adjusted EBITDA climbed 14.9% to AU$132.6 million.
Iress Limited (ASX: IRE) recorded a strong market reaction following the release of its FY25 financial results, with the stock rising nearly 12.56% at the time of writing to AU$7.620. The uplift reflects improved earnings quality, margin expansion, and a strengthened balance sheet position.
FY25 Financial Performance
For FY25, headline Adjusted EBITDA increased 2.6% to AU$136.2 million, while UPAT advanced 16.6% to AU$73.9 million. Underlying EPS improved 16.4% to 39.6 cents per share.
Within the Continuing Business, revenue rose 6.5% to AU$504.3 million and Adjusted EBITDA increased 14.9% to AU$132.6 million, with margins expanding to 26.3%. UPAT for the Continuing Business grew 34.3% to AU$72.8 million.
Balance Sheet and Capital Management
The company completed the divestment of its Superannuation and QuantHouse businesses during FY25, strengthening financial flexibility. Proceeds were used to reduce debt, bringing leverage down to 0.5x. The Board declared a fully franked final dividend of 13.0 cents per share.
FY26 Guidance
Management guided to FY26 revenue of AU$520–528 million and Cash EBITDA of AU$116–123 million, representing double-digit growth at the midpoint. The company is targeting a +25% Cash EBITDA margin exit run-rate by Q4 FY26.
Note:
The data presented above is based on information available at the time of writing.
Disclaimer for Kapitales Research
The materials provided by Kapitales Research, including articles, news, data, reports, opinions, images, charts, and videos ("Content"), are intended for personal, non-commercial use only. The primary goal of this Content is to educate and inform readers. This Content is not meant to offer financial advice, nor does it include any recommendation or opinion that should be relied upon for making financial decisions. Certain Content on this platform may be sponsored or unsponsored, but it does not serve as a solicitation or endorsement to buy, sell, or hold any securities, nor does it encourage any specific investment activities. Kapitales Research is not authorized to provide investment advice, and we strongly advise users to seek guidance from a qualified financial professional, such as a financial advisor or stockbroker, before making any investment choices. Kapitales Research disclaims all liability for any direct, indirect, incidental, or consequential damages arising from the use of the Content, which is provided without any warranties. The opinions expressed by contributors or guests are their own and do not necessarily reflect the views of Kapitales Research. Media such as images or music used on this platform are either owned by Kapitales Research, sourced through paid subscriptions, or believed to be in the public domain. We have made reasonable efforts to credit sources where appropriate. Kapitales Research does not claim ownership of any third-party media unless explicitly stated otherwise.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
Is Iress Limiteds Strong FY25 Result Driving a 12.56% Share Price Surge?
Highlights
• Iress Limited (ASX: IRE) shares surged nearly 12.56% at the time of writing, trading at AU$7.620 after gaining AU$0.850.
• FY25 headline UPAT rose 16.6% to AU$73.9 million, with Underlying EPS up 16.4% to 39.6 cents per share.
• Continuing Business revenue increased 6.5% to AU$504.3 million, while Adjusted EBITDA climbed 14.9% to AU$132.6 million.
Iress Limited (ASX: IRE) recorded a strong market reaction following the release of its FY25 financial results, with the stock rising nearly 12.56% at the time of writing to AU$7.620. The uplift reflects improved earnings quality, margin expansion, and a strengthened balance sheet position.
FY25 Financial Performance
For FY25, headline Adjusted EBITDA increased 2.6% to AU$136.2 million, while UPAT advanced 16.6% to AU$73.9 million. Underlying EPS improved 16.4% to 39.6 cents per share.
Within the Continuing Business, revenue rose 6.5% to AU$504.3 million and Adjusted EBITDA increased 14.9% to AU$132.6 million, with margins expanding to 26.3%. UPAT for the Continuing Business grew 34.3% to AU$72.8 million.
Balance Sheet and Capital Management
The company completed the divestment of its Superannuation and QuantHouse businesses during FY25, strengthening financial flexibility. Proceeds were used to reduce debt, bringing leverage down to 0.5x. The Board declared a fully franked final dividend of 13.0 cents per share.
FY26 Guidance
Management guided to FY26 revenue of AU$520–528 million and Cash EBITDA of AU$116–123 million, representing double-digit growth at the midpoint. The company is targeting a +25% Cash EBITDA margin exit run-rate by Q4 FY26.
Note:
The data presented above is based on information available at the time of writing.
Disclaimer for Kapitales Research
The materials provided by Kapitales Research, including articles, news, data, reports, opinions, images, charts, and videos ("Content"), are intended for personal, non-commercial use only. The primary goal of this Content is to educate and inform readers. This Content is not meant to offer financial advice, nor does it include any recommendation or opinion that should be relied upon for making financial decisions. Certain Content on this platform may be sponsored or unsponsored, but it does not serve as a solicitation or endorsement to buy, sell, or hold any securities, nor does it encourage any specific investment activities. Kapitales Research is not authorized to provide investment advice, and we strongly advise users to seek guidance from a qualified financial professional, such as a financial advisor or stockbroker, before making any investment choices. Kapitales Research disclaims all liability for any direct, indirect, incidental, or consequential damages arising from the use of the Content, which is provided without any warranties. The opinions expressed by contributors or guests are their own and do not necessarily reflect the views of Kapitales Research. Media such as images or music used on this platform are either owned by Kapitales Research, sourced through paid subscriptions, or believed to be in the public domain. We have made reasonable efforts to credit sources where appropriate. Kapitales Research does not claim ownership of any third-party media unless explicitly stated otherwise.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au